Spots Global Cancer Trial Database for Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Official Title: A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.
Study ID: NCT01810770
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and efficacy (Overall survival \[OS\]) of multiple doses of Ra-223 dichloride in an Asian population of subjects with CRPC metastatic to the bone.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
, Guangzhou, Guangdong, China
, Guangzhou, Guangdong, China
, Nanjing, Jiangsu, China
, Nanjing, Jiangsu, China
, Beijing, , China
, Beijing, , China
, Beijing, , China
, Beijing, , China
, Beijing, , China
, Guangzhou, , China
, Shanghai, , China
, Shanghai, , China
, Shanghai, , China
, Shanghai, , China
, Shanghai, , China
, Donggu,, Gwangju Gwang''yeogsi, Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Singapore, , Singapore
, Singapore, , Singapore
, Singapore, , Singapore
, Singapore, , Singapore
, Taipei City, Taipei, Taiwan
, Kaohsiung, , Taiwan
, Taipei, , Taiwan
, Taoyuan, , Taiwan
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
